Astra and Acasti throw the Amarin bulls more fodder
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
Clinical developments over the Christmas period 2019
The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.
Acasti plays catch-up to Amarin’s Vascepa
Two phase III studies could determine whether the Canadian biotech has an approvable product, but the setting will initially be narrow.